Effects of probiotic yogurt ingestion on inflammation and intestinal function in patients with inflammatory bowel disease

Effects of probiotic yogurt ingestion on inflammation parameters, micro flora and intestinal permeability in patients with inflammatory bowel disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105106431N1

Enrollment

210

Registered

2012-06-05

Start date

2012-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Inflammatory bowel disease. Condition 2: Inflammatory bowel disease. Ulcerative colitis Crohn's disease

Interventions

Intervention 1: Control group: non-probiotic yogurt ingestion for 8 weeks (250 grams daily). Intervention 2: Intervention group: probiotic yogurt ingestion for 8 weeks (250 grams daily).

Treatment - Other

Control group: non-probiotic yogurt ingestion for 8 weeks (250 grams daily)

Intervention group: probiotic yogurt ingestion for 8 weeks (250 grams daily)

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Ulcerative colitis or crohn's disease patients; 2- No history of using probiotic and prebiotic supplements within last 3 months; 3- No history of using antioxidant vitamin supplements within last 3 months; 4- No history of using omega-3 fatty acids supplements within last 3 months; 5- No history of using antibiotic drugs within last 3 months; 6- No history of other inflammatory diseases like rheumatoid arthritis and infectious disease; 7- No history of other gastrointestinal disease; 8- Body mass index(BMI) between 18.5 and 30; 9- No pregnancy and lactating stage in women; 10- Interested in participation and complete consent form. Exclusion criteria: 1-Not interested to continue the study; 2-Need for change drug's doses or types during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IL-1beta. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.;TNF-alpha. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.;Intestinal microflora. Timepoint: At baseline and at the end. Method of measurement: Real-time PCR.;Intestinal permability. Timepoint: At baseline and at the end. Method of measurement: HPLC.;IL-6. Timepoint: at baseline and at the end. Method of measurement: ELISA commercial kits.;CRP. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.;IL-10. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.	—

Measure

Time frame

IL-1beta. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.;TNF-alpha. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.;Intestinal microflora. Timepoint: At baseline and at the end. Method of measurement: Real-time PCR.;Intestinal permability. Timepoint: At baseline and at the end. Method of measurement: HPLC.;IL-6. Timepoint: at baseline and at the end. Method of measurement: ELISA commercial kits.;CRP. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.;IL-10. Timepoint: At baseline and at the end. Method of measurement: ELISA commercial kits.

—

Secondary

Measure	Time frame
Dietary intake of different fatty acids. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of energy. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of macronutrient. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of cholestrol. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of antioxidant vitamins. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of fiber. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of calcium. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.	—

Measure

Time frame

Dietary intake of different fatty acids. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of energy. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of macronutrient. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of cholestrol. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of antioxidant vitamins. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of fiber. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.;Dietary intake of calcium. Timepoint: At baseline and at the end. Method of measurement: Nutritionist IV, a software program.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Shadnoush

Food Science and Technology Department, Nutritional Institute

mshadnoush@gmail.com+98 21 2240 1423

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026